A Clinical Study on Plasma Biomarkers for Deciding the Use of Adjuvant Corticosteroid Therapy in Bronchopulmonary Dysplasia of Premature Infants

Overview

Journal Int J Med Sci

Specialty General Medicine

Date 2021 Jun 9

PMID 34104089

Citations 2

Authors

Haiyan Zhu

Yian Tian

Huaiping Cheng

YaFei Zheng

Wei Wang

Tianping Bao

Rong Wu

Zhaofang Tian

Affiliations

Soon will be listed here.

Abstract

The study was designed to investigate some plasma markers which help us to decide the use of adjuvant corticosteroid therapy in bronchopulmonary dysplasia (BPD) of premature infants. Thirty BPD infants were treated by dexamethasone. Among these cases, dexamethasone was significant effective in 10 cases, and no significant effective in 20 cases. These patients were divided into two groups as the significant effect (SE) group (n=10) and the non-significant effect (NE) group (n=20) according to the curative effect of dexamethasone. Fifteen non-BPD infants with gestational age and gender matching were selected as the control group. Plasma samples before and after dexamethasone treatment were collected from three infants chosen randomly from SEG for the data-independent acquisition (DIA) analysis. ELISA was further used to detect the levels of differential proteins LRP1 and S100A8 in all individuals, including SE, NE and control groups. DIA analysis results showed that after dexamethasone treatment, there were a total of 52 plasma proteins that showed significant differences, of which 43 proteins were down-regulated and 9 proteins were up-regulated. LRP1 and S100A8 were two plasma proteins that were significantly changed after dexamethasone treatment. Compared with the control group, plasma LRP1 was significantly increased in BPD. Interestingly, the plasma concentration of LRP1 in the NE group was significantly higher than that in the SE group. S100A8, as an indicator of plasma inflammation, was significantly higher in BPD than the control group. Unlike LRP1, there was no significantly difference between the SE and NE group (P=0.279) before dexamethasone treatment. Elevated plasma LRP1 and S100A8 in BPD infants are two indicators that correlated with the efficacy of dexamethasone, and might be used as biomarkers for deciding the use of adjuvant corticosteroids therapy in the BPD.

Citing Articles

Salivary cortisol is not associated with dexamethasone response in preterm infants with evolving bronchopulmonary dysplasia.

Lewis T, Jensen E, Courtney S, Slaughter J, Kielt M, Iyer N J Perinatol. 2024; .

PMID: 39567652 DOI: 10.1038/s41372-024-02177-x.

Role of the LRP1-pPyk2-MMP9 pathway in hyperoxia-induced lung injury in neonatal rats.

Zheng Y, Zhu H, Wang W, Hu J, Bao T, Tian Z Zhongguo Dang Dai Er Ke Za Zhi. 2021; 23(12):1289-1294.

PMID: 34911615 PMC: 8690715. DOI: 10.7499/j.issn.1008-8830.2108125.

References

Kong X, Xu F, Wu R, Wu H, Ju R, Zhao X . Neonatal mortality and morbidity among infants between 24 to 31 complete weeks: a multicenter survey in China from 2013 to 2014. BMC Pediatr. 2016; 16(1):174. PMC: 5094017. DOI: 10.1186/s12887-016-0716-5. View

Magagnotti C, Matassa P, Bachi A, Vendettuoli V, Fermo I, Colnaghi M . Calcium signaling-related proteins are associated with broncho-pulmonary dysplasia progression. J Proteomics. 2013; 94:401-12. DOI: 10.1016/j.jprot.2013.10.007. View

Martin J, Osterman M . Describing the Increase in Preterm Births in the United States, 2014-2016. NCHS Data Brief. 2018; (312):1-8. View

Mammel M, Green T, Johnson D, Thompson T . Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983; 1(8338):1356-8. DOI: 10.1016/s0140-6736(83)92139-6. View

Scott N, Swanson R, Al-Hammadi N, Domingo-Gonzalez R, Rangel-Moreno J, Kriel B . S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis. J Clin Invest. 2020; 130(6):3098-3112. PMC: 7259997. DOI: 10.1172/JCI130546. View

Rigo V, Lefebvre C, Broux I . Surfactant instillation in spontaneously breathing preterm infants: a systematic review and meta-analysis. Eur J Pediatr. 2016; 175(12):1933-1942. DOI: 10.1007/s00431-016-2789-4. View

Pereira-Fantini P, Tingay D . The proteomics of lung injury in childhood: challenges and opportunities. Clin Proteomics. 2016; 13:5. PMC: 4772280. DOI: 10.1186/s12014-016-9106-0. View

Spijkers-Hagelstein J, Schneider P, Hulleman E, de Boer J, Williams O, Pieters R . Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia. Leukemia. 2012; 26(6):1255-65. DOI: 10.1038/leu.2011.388. View

Stoll B, Hansen N, Bell E, Walsh M, Carlo W, Shankaran S . Trends in Care Practices, Morbidity, and Mortality of Extremely Preterm Neonates, 1993-2012. JAMA. 2015; 314(10):1039-51. PMC: 4787615. DOI: 10.1001/jama.2015.10244. View

10.

Miyake F, Ito M, Minami H, Tamura M, Namba F . Management of bronchopulmonary dysplasia in Japan: A 10-year nationwide survey. Pediatr Neonatol. 2019; 61(3):272-278. DOI: 10.1016/j.pedneo.2019.11.007. View

11.

Michael Z, Spyropoulos F, Ghanta S, Christou H . Bronchopulmonary Dysplasia: An Update of Current Pharmacologic Therapies and New Approaches. Clin Med Insights Pediatr. 2018; 12:1179556518817322. PMC: 6295761. DOI: 10.1177/1179556518817322. View

12.

Kotsiou O, Papagiannis D, Papadopoulou R, Gourgoulianis K . Calprotectin in Lung Diseases. Int J Mol Sci. 2021; 22(4). PMC: 7915440. DOI: 10.3390/ijms22041706. View

13.

Onland W, Offringa M, van Kaam A . Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev. 2017; 8:CD002311. PMC: 6483527. DOI: 10.1002/14651858.CD002311.pub4. View

14.

Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C . Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial. Lancet. 2016; 387(10030):1827-36. DOI: 10.1016/S0140-6736(16)00202-6. View

15.

Marzolo M, von Bernhardi R, Bu G, Inestrosa N . Expression of alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP) in rat microglial cells. J Neurosci Res. 2000; 60(3):401-11. DOI: 10.1002/(SICI)1097-4547(20000501)60:3<401::AID-JNR15>3.0.CO;2-L. View

16.

Lu X, Wang C, Wu D, Zhang C, Xiao C, Xu F . Quantitative proteomics reveals the mechanisms of hydrogen-conferred protection against hyperoxia-induced injury in type II alveolar epithelial cells. Exp Lung Res. 2019; 44(10):464-475. DOI: 10.1080/01902148.2019.1601296. View

17.

Stewart A, Brion L, Ambrosio-Perez I . Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2011; (9):CD001817. PMC: 7068169. DOI: 10.1002/14651858.CD001817.pub2. View

18.

Huang S, Ding Z, Xiang H, Fu L, Fei J . Association Between Serum S100A8/S100A9 Heterodimer and Pulmonary Function in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Lung. 2020; 198(4):645-652. DOI: 10.1007/s00408-020-00376-9. View

19.

OShea T, Kothadia J, Klinepeter K, Goldstein D, Jackson B, Weaver 3rd R . Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999; 104(1 Pt 1):15-21. DOI: 10.1542/peds.104.1.15. View

20.

Yoder B, Harrison M, Clark R . Time-related changes in steroid use and bronchopulmonary dysplasia in preterm infants. Pediatrics. 2009; 124(2):673-9. DOI: 10.1542/peds.2008-2793. View